These findings indicate that the circRNA_0046366 or circRNA_0046366/miR-34a/PPAR pathways can represent epigenetic mechanisms underlying hepatic steatosis and may become a therapeutic alternative in NAFLD treatment [139]. The gene discussed is PPARA; the disease is fatty liver disease.